drugset / Trial / NCT02480166

Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6

NCT02480166

Phase 4 Completed 60 enrolled Stanford University Gilead Sciences · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objectives of this study are to describe the efficacy of: 1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6 2. 12-week treatment of SOF/LED for all other HCV-6 populations

Timeline

Start
2015-06
Primary completion
2016-10
Completion
2016-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ledipasvir Small molecule 90 mg Oral
Subject Sofosbuvir Small molecule 400 mg Oral

Indications

No indication recorded.